Roger Stupp, MD, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More